Pamela Russell

Positions

Emeritus Professor, Head of Biomedical Imaging and Prostate Cancer Models, APCRC-Q
Emeritus Professor, IHBI, QUT
Adjunct Professor, Centre for Advanced Imaging, University of Queensland.

Contact Details

Email: pamela.russell@qut.edu.au
Phone: +61 7 3443 7240

Related websites and profiles

Australian-Canadian Prostate Cancer Research Alliance

Queensland University of Technology Profile

Qualifications

DipEd, Canberra University, Australia, 1979
PhD, Autoimmunity, Sir Gustav Nossal, Walter & Eliza Hall Institute of Medical Research, Melbourne, 1968
MSc, Autoimmunity, Sir Macfarlane Burnet, Walter & Eliza Hall Institute of Medical Research, Melbourne, 1965
BSc, Science (Biochemistry/Microbiology) University of Melbourne, Australia, 1963

Biography

Emeritus Professor Russell, AM (PhD, Dip Ed) has built an international reputation for her work in urological cancers - in particular bladder and prostate cancers. In 2003, she was awarded Membership of the Order of Australia (AM) for her research on bladder and prostate cancer and, in 2015, she was made a fellow of the Australian Academy of Health and Medical Sciences, Limited.

Prof Russell has extensive expertise in establishing cell lines and rare xenografts from primary human tumours and generating urological cancer models, and collaborates widely, within Australia and overseas in USA and Europe. Her recent research focus has been on developing new methods for prostate specific-membrane antigen (PSMA) targeted imaging using 19F-MRI, and studying new biomarkers in exosomes, which may indicate/predict the response of CRPC to chemotherapy.

Nationally, she helped to initiate the Australian Genitourinary Oncology Group and the Prostate Cancer Foundation of Australia (PCFA) (of which she is a life member). From 2007 to 2010 Prof Russell served as an inaugural Director/Secretary of the Australasian Urological and Prostate Cancer Clinical Trials Group (ANZUP). She is also an Australian editor for Urological Research and a member of Movember’s Global Scientific Committee.

In 2006 she received a prize for outstanding research alumnus of Sydney’s Kolling Institute of Medical Research, was made a life member of the Australasian Gene Therapy Society in 2009, and in 2010, PCFA’s Prostate Cancer Researcher of the Year in Australia. She has also served on Movember’s Global Action Plan Scientific Committee (2010-14) and Research Advisory Committees.

She was Professor of Medicine, University of New South Wales (UNSW) and Director of the Oncology Research Centre at the UNSW School of Medicine at Prince of Wales Hospital, Sydney from 1992-2008.

Read More ▼: After training in immunology at the Walter & Eliza Hall Institute of Medical Research in Melbourne with Sir Macfarlane Burnet and Sir Gustav Nossal, she changed her research focus to cancer in 1984, and with Dr Derek Raghavan, set up the Urological Cancer Research Unit at Sydney University.

She has procured >$35M in grants, has published >200 peer reviewed articles, as well as several reviews and book chapters, edited one book and co-authored six patents. She is currently funded by the NHMRC and Movember GAP programs.

Prof Russell has been on peer review committees for the National Health and Medical Research Committee (NHMRC), Cancer Council Australia, Cure Cancer Australia, and regularly reviews papers from international journals. She has delivered presentations or chaired sessions at numerous international prostate cancer meetings.

She has trained 13 Honours students, 7 BSc (Med) students, 3 Masters’ students, 14 PhD and 1 MD student and 31 post-doctoral fellows.

Awards and grants

Awards

2015	Fellow of the Australian Academy of Health and Medical Science, Limited
2010	Inaugural Prostate Cancer Foundation of Australia Prize and Lecture for Outstanding Excellence
2010	Prostate Cancer Foundation of Australia's Researcher of the year
2009	Made Life Member, Australasian Gene Therapy Society
2009	Alban Gee Prize for best poster presentation at USANZ
2007	Member of the year, listed in Madison's Who's Who
2006	Made Honorary Life Member, Prostate Cancer Foundation of Australia
2006	Awarded prize for outstanding alumni of Kolling Institute of Medical Research (75th Jubilee)
2005	Listed in Marquis Who's Who in Medicine and Healthcare, USA
2003-2005	Listed in Who's Who, Australia
2003	Platinum Nomination for the CSIRO Chairman's medal. Gene Therapy: A new approach for treating prostate cancer
2003	Order of Australia (AM) for outstanding contributions to prostate and bladder cancer research
1962	Dunlop Rubber prize for Biochemistry
1960	Commonwealth Scholarship

Grants

2017-2018	Translational Research Institute (TRI) Spore Grant $80,000	MicroRNA replacement therapy for indolent and aggressive prostate cancer.	Batri J, Russell PJ, Vela I, Cristina A
2016-2018	National Health and Medical Research Council (NHMRC) Category 1 APP108043 $633,757	Immunopolymeric drugs for prostate cancer therapy	Thurecht K, Russell PJ, Mahler S, Boyd A, Howard C (AIs: Thompson L, Heathcote P, Straw R).
2016-2018	NHMRC Category 1 APP 108043 $541,000	The Microniche: A novel in-vitro and in-vivo prostate cancer model system	Doran MR, Vela I, Tse B, Russell PJ (AIs Pettit A, Wang C, Clements JA).
2015-2017	Australian Research Council (ARC) Linkage LP150100703 $360,000	Next generation hybrid nanomaterials: investigating anti-PET as a component in bispecific antibodies as a novel biomolecule couple technology	Thurecht KJ, Mahler S, Russell PJ, Walsh D, Campbell.
2015-2017	Prostate Cancer Foundation of Australia (PCFA) / Movember Foundation $3,250,000	Movember Revolutionary Team Award 3: Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer.	Butler L,Collaborators: Tilley W, Hoy A, Wittert G, Nelson CC, Scott A, Swinnen J, Clayton A,Weickhardt A, Davis I, Power C, Bianco-Miotto T, Russell PJ (AI), Brooks D, Sutherland P, Parnis F
2015-2017	NHMRC Development Grant Category 1 APP1093539 $700,000	Novel prostate cancer target for diagnosis, imaging, detection of recurrence and response to therapy	Nelson CC, Russell PJ, Walsh BJ, Campbell D.
2014-2017	PCFA Movember Revolutionary Team Award $4,250,000	Adaptive response to androgen targeted therapies: A strategic offensive on resistance	Nelson CC, et al. (AIs, include PJ Russell).
2015-2016	World Cancer Research (Former AICR), 103624 pounds ~$168,907	A humanized in vivo model to test novel therapeutic strategies against prostate cancer bone metastasis.	Hutmacher D, Denham J, Russell PJ, Williams ED, Levesque J-P, Holzapfel BA.
2015	ARC – Linkages, Infrastructure and Equipment Fund (LIEF) Category 1 LEIF 50100067 $390,000	The Vevo 2100 Micro-ultrasound plus LAZR Photoacoustic Imaging Platform	Russell PJ, Gobe G, Herington A, Langton C, Thurecht K, Brereton I, Frazer I, Fielding A, Hutmacher D, Hill M
2015	Australian Cancer Research Foundation (ACRF) $4 million ($2.5 m obtained)	ACRF Facility for Molecular Imaging Agents (AFMIAC)	Reutens D, Cooper MA, Smith MT, Boyd A, Richards L, Bartlett PF, Russell PJ, Walker DG, Bhalla R, Barth M, Palmeri C, Thurecht K, Venkatachalam T, Allavena R, Straw R, Tesiram Y, Bunt J, Francois M, Osborne G.
2014-2015	PCFA/Movember Foundation	Movember Global Action Plan Xenograft Project Grant	Williams ED, Russell PJ, Nelson C
2014	TRI Inter-Institutional Collaborative Research Funding Award $25,000	Diagnosing small renal masses; solving the clinical problem of how best to manage patients with kidney neoplasms that are not life threatening	Gobe G, Wood S, Coward J, Russell PJ, Saunders N, Lott W (AI Hemamali Samaratunga).
2014-2015	Movember Xenograft project Grant $112,000	Global Action Plan-Xenografts)	Williams ED, Russell PJ, Nelson CC
2014-2015	Gallipoli Medical Research Foundation $50,000	Evaluation of PSMA-based positron emission tomography and magnetic resonance imaging for detection of multiple cancer foci in localized prostate cancer patients.	Heathcote P, Thomas P, Wood S, Greenslade S, Lampe G, Shephard B, Nelson CC, Russell PJ
2013-2017	Australian Government Department of Health and Aging $6,163,000	Australian Prostate Cancer Research Centre – Queensland	Nelson CC, Clements J, Russell PJ, Herington A, Chopin L, Hutmacher D, O’Byrne K, Graves N, Yates P, Williams ED, Richard D, Wood S, Vela I, Heathcote P, Lehman M, Gogna K, McCaffrey E, Greenslade S, Lampe G, Shepherd B.
2013-2014	Movember Global Exosome Biomarker Project Grant $227,000	Development of assays for the capture and detection of prostate cancer-derived exosomes and exosomal markers.	Russell PJ, Soekmadji C, Nelson CC, Hovens C.
2013-2016	NHMRC APP1046831 Category 1 $545,362	Imaging for prostate cancer theranostics	Russell PJ, Whittaker A, Thurecht K (AIs, Nelson C, Coswin G, Heston WD, Emberton M.)
2012	PCFA NDDA0411 $100,000	Simultaneous imaging and drug delivery for prostate cancer theranostics	Russell PJ, Whittaker A, Thurecht K, Heston WW.
2012-2015	NHMRC APP1031228 Category 1 $606,134	Identification of PACE-1 as a novel therapeutic target for the treatment of prostate cancer	Ling, MT, Quinn R, Russell PJ, (AI: Nelson, C)
2011	ARC - LIEF Category 1 $330,000	Comprehensive Cell Imaging Facility	Clements J, McMillan N, Whitehead JB, Beagley KW, Russell PJ, Nelson CC, Hutmacher DW, Atkinson MK, Dawson PA, Frazer IH, Gonda TJ, Hooper JD, Levesque JP J, McGuckin MA, Munster DJ, Rice AM, Thomas R, Vuckovic S, Waterhouse NJ.
2011-2014	ARC Discovery Category 1 DP110103890 $436,000	Development and validation of virtual epithelial cancer models using an integrated modelling and experimental three-dimensional approach	Hutmacher D, McElwain DL, Russell PJ, Flegg JA, Loessner D, Clements J, Dalton PD, Byrne HM.
2011-2013	NHMRC APP1010141 Category 1 $596,306	KLK4 is a master regulator of tumour microenvironment remodelling in prostate cancer and bone metastasis	Clements J, Nelson C, Hutmacher D, Russel PJ.
2010-2011	Queensland Cancer Council 614273 $196,500	The role of KLK4 in prostate cancer progression	Clements JA, Hutmacher DW, Nelson CC, Russell PJ.
2010	PCFA $124,798	Targeted nanoparticles for imaging prostate cancer	Russell PJ, Khatri A, Cowin G, Thierry B, Power C.
2010	PCFA $30,000	Application for a Syngene G:Box Chemi XT unit	Russell PJ, Nelson CC, Lin P, Clements JA, Harris J, Hooper J, Chopin L, Herington A, Stephenson SA.
2009	Cancer Institute, NSW, Research Equipment Grant $300,000	Aperio Scan Scope Virtual Slide Scanner for collaborative cancer histopathology	Hawkins N, Ward R, Apte M, Russell PJ, Sewell W.
2008-2009	NHMRC Development Category 1 APP497290 $160,500	Potential therapeutic roles for a protease inhibitor	Harris J, Clements J, Russell PJ.
2008-2010	Cancer Australia and PCFA (NHMRC510239) $587,525.	Preclinical evaluation of novel prostate-targeted nanoparticles for imaging primary and metastatic prostate cancer	Rusell PJ, Amal R, Walsh BJ, Bucci J, de Souza P. Changed in 2009 to : Russell PJ, Thierry B, Walsh BJ, Bucci J, de Souza P, Khatri A. $584,000
2008	Goldstar Award, UNSW $40,000	Preclinical evaluation of novel prostate-targeted nanoparticles for imaging primary and metastatic prostate cancer	Rusell PJ, Amal R, Walsh BJ, Bucci J, de Souza P. Awarded but not taken up as ARC Linkage successful
2008-2010	ARC Linkage Grants LP0882720 $372,000	Numerical modelling and experimental studies to design and engineer nanoparticulate systems for bioapplications	Amal R, Russell PJ, Walsh BJ, Gooding J.
2008-2010	NHMRC APP510238 Category 1 $432,000	Combined novel tumour-targeted molecular and traditional chemotherapy for treating androgen refractory prostate cancer	Russell PJ.
2008-2010	UNSW Foundation & PCFA $300,000	Studies of bone metastasis from prostate cancer	Russell PJ, Power C.
2007	Cancer Inst. NSW, $240,200	Establishment of networking data base and animal support for live animal imaging	Russell PJ, Khachigian L, Crowe PJ, Rae C, Wlash W, Haber M, Lock R, Yang j-lL, Tuch B, Rose M, Price W, Power C.
2007	UNSW equipment grant $1,100,000	Major Research and Infra-structure equipment: Vevo and intra-vital microscopy	Khachigian L, Chesterman C, Hogg P, Jessup W, Chong B, Kritharides L, Gaus K, Haber M, Norris M, Kavallaris M, Lock R, Brown AJ, Gooding J, Russell PJ, Power C, Amal R, Rose M, Geczy C, Morris M, Waite P, Ashwell K, Hill M, Carrive P, Stoodley M, Brew B, Tuch B, Kuldip S.
2007	UNSW, Major Research and Infrastructure $476,000	MicroCT scanner	Russell PJ, Waite P, Geczy C, Rose M, Khachigian L, Tuch B, Walsh W, Stoodley M, Yang J-L, Carrive P, Lovell N, Power C, Amal R.
2007-2009	Cancer Council NSW $300,000	Secreted phospholipase A2 in prostate cancer	Scott K, Graham G, Dong Q, Russell PJ.
2007-2009	Cancer Council NSW $299,650	Chemo-sensitising pathways in ovarian cancer	de Fazio A, Harnett P, Russell P, Associate Investigators: Bowtell D, Guminski A, Byth K, Sharma R.
2007-2009	ARC - LIEF LP0774951 $75,000	Identification of novel biomarkers in tears for prostate cancer diagnosis and prognosis	Li Y, Willcox MD, Cozzi PJ, Russell PJ, Walsh BJ, Zhao Z.
2007-2009	Sydney Foundation of Medical Research $225,000	Studies of bony metastases	Russell PJ, Power C
2007-2009	UNSW Faculty of Medicine Strategic Initiatives Grant $300,000	Establishment of Biomedical Nanotechnology Centre	Kavallaris M, Davis T, Khachigian LM, Norris M, Tuch B, Russell P, Cunningham A, Bulmus V.
2006	MSW Cancer Institute: Equipment grant $300,000	Imaging system for live small animals (Xenogen IVIS 100 System)	Russell PJ, Crowe PJ, Haber M, Khachigian L, Lock R, Ormandy C, Rose M, Bucci J, Yang J-L, Power C, Khatri A, Kavallaris M, Rawlinson W.
2006-2007	Novartis $130,000	Inhibition of bony metastases by therapeutic agents from Novartis (alone and in combination) using prostate cancer RM-1(BM)GFP metastasis model in immunocompetent mice	Power C, Russell PJ
2006-2008	NSW Cancer Council $375,000	The role of the TGF-b superfamily cytokine MIC-1 in the biology of cancer	Breit S, Russell PJ
2005	Prince of Wales Clinical School Research Enhancement Grant $13,000	The significance of mutations in the FGFR3 gene to bladder cancer progression.	Jackson P, Russell PJ, Hung T-T, Roscioli T.
2005	Prince Henry Centenary Foundation, & Children’s Hospital $500,000	Purchase of confocal microscope	Cunningham A, Kavallaris M, Russell PJ
2005	Prince of Wales Clinical School Research Enhancement Grant $13,000	Relationship of EGFR receptor mutation and gene variation in its signalling pathways to the synergistic effect of interferon-alpha plus erlotinib in treatment of human colon cancer cell lines.	Goldstein D, Yang J-L, Russell PJ
2005-2009	NSW Cancer Institute: Translational grant $3,750,000	Identification and validation of molecular markers of prognosis and therapeutic responsiveness in prostate cancer	Clarke S, Henshall S, Russell PJ, Horvath L, Sutherland R, Kench J, Lee C-Soon, Molloy PL, Grygiel J, Stricker P, Boyer M.
2005	NSW Cancer Institute: Research Infrastructure grant	Infrastructure support for an established cancer genetics/genomics facility.	Hayes V, Ormandy C, Breit S, Butt A, Clark S, Daly R, Grygiel J, Henshall S, Horvath L, Kaplan W, Kench J, Kohonen-Corish M, Musgrove E, O’Brien P, Russell PJ, Sutherland R, Ward RL.
2005-2006	NSW Cancer Institute, Research Infrastructure grant $214,625	SESAHS Consortium for rational therapeutics	Ward R, Links M, Goldstein D, Russell PJ
2005	Rebecca Cooper Foundation $16,000	Purchase of a tissue slicer	Katri A, Russell PJ
2004-2006	Department of Veterans’ Affairs Australia $490,500	Oncogenic action and therapeutic potential of PLA2 in prostate cancer.	Dong Q, Scott K, Graham G, Russell PJ
2005	UNSW Faculty of Medicine Enhancement Grant $12,000	To purchase real time PCR.	Russell PJ, Erlich J
2004-2008	NHMRC Enabling Grant $2,100,000	Prostate Cancer Tissue Banking.	Clements JA, Risbridger, V Marshall, D Roder, J Stahl, F Gardiner, D Nicol, M Frydenberg, J Pederson, P Stricker (PJ Russell AI)
2004-2007	US Army Defense Department, USA W81XWH-1-004 New Investigator Award $300,000	Control of micrometastatic prostate cancer using multiple alpha targeted therapy	Li Y, Cozzi PJ, Rizvi SMA, Diwan A, Allen BJ, Russell PJ
2004	Prince of Wales Hospital Oncology Institute Grant $25,000	Studies of gene array of p53-expressing human prostate cancer cell lines	Blair J, Russell PJ
2004	Prince of Wales Hospital Oncology Institute Grant $42,000	Studies of chemotherapy and radiotherapy of prostate cancer	Zhang AL, Milross C, Russell PJ
2004	Prince of Wales Hospital Oncology Institute Grant $20,000	Top up for gene therapy work	Russell PJ, Khatri A.
2004	Cure Cancer Foundation of Australia $48,028 awarded but not taken up as Dr Zhao moved.	Purification, identification and functional studies of proteases expressed in prostate cancer cell lines – a functional proteomic study	Zhao J, Russell PJ
2004	Faculty of Medicine, Enhancement grant UNS $15,000	To purchase fluorescence microsopy imaging equipment	Russell PJ, Erhlich J.
2004	Clive and Vera Ramaciotti $29,878	Microscopy equipment	Erlich J, Russell PJ
2004	NHMRC equipment grant $60,000	Purchase of fluorescence microscopy imaging equipment	Russell PJ, Erlich J
2003	Cure Cancer Foundation $60,000	Purchase of a faxitron	Broan JM, Russell PJ
2003-2005	National Institute of Health and National Institute of Diabetes and Digestive and Kidney Diseases Bethesda DK067681-01 US $216,000 (~A$342,857)	The role of IL18 in the spread of prostate cancer to the bone	Russell PJ, Martiniello-Wilks R, Zhang A.
2003-2005	Department of Defense, US Army, Alternative Funding DAMD17-02-1-0107 US$522,000 (~A$900,000)	Formulated delivery of enzyme/pro-drug and cytokine gene therapy to promote immune reduction of treated and remote tumors in mouse models of prostate cancer.	Russell PJ, Both GW, Molloy PL and others from CSIRO
2002-2004	Department of Defense, US Army, New Idea Award DAMD17-02-1-0108 US$456,000 (~A708,592)	Studies of the role of p53 mutations in metastases of prostate cancer to bone.	Russell PJ, Brown JM
2004	Sydney Foundation for Medical Research $151,000	Studies of prostate cancer	Russell PJ
2002-2003	Sydney Foundation for Medical Research $176,000	Studies of proteases in prostate cancer	Russell PJ, Zhao Z
2001	Australian Kidney Foundation, Equipment grant $13,224	Equipment grant	Russell PJ
2001	Clive and Vera Ramaciotti Foundation $15,831 (equipment)	Identification of proteases associated with prostate cancer invasion and progression	Daja M, Russell PJ
1999-2003	FH Faulding support for CSIRO, SESAHS And AusIndustry Start Plus, Funds for ORC, POWH: $1,220,380	Studies of gene therapy	Russell PJ and team
2000-2001	Sydney Foundation for Medical Research $248,424	Studies of proteases produced by prostate cancer cells, (includes equipment)	Russell PJ, Daja M
1998-2001	AusIndustry grant, for CSIRO, CSL and SESAHS $1,000,000	Lytic peptides for cancer therapy	CSL, CSIRO, Russell PJ teams
1999	Australasian Urological Foundation $20,000	Cytodine methylation of regulatory sequences near glutaehione-S transferase gene in the peripheral blood of patients with prostate cancer	Russell PJ, Patel M
1999	Leo and Jenny Leukaemia and Cancer Foundation $49,489	The role of KAI-1 in invasive bladder cancer.	Jackson P, Russell PJ
1999-2001	NHMRC APP990152 $315,000 Category 1	Therapy for prostate cancer using the prostate specific membrane antigen for targeting	Russell PJ, Molloy PL, Both GW, Jackson P
1998-1999	NSW Cancer Council $150,000 Category 1	Gene therapy for androgen-independent prostate cancer: Preclinical Studies	Russell PJ, Molloy PL, Both GW
1997-1999	Sydney Foundation for Medical Research $357,270	The relationship between protease activity and onset and progression.	Russell PJ, Whittaker R.
1996	Leo and Jenny Leukaemia and Cancer Foundation $5000	The role of KAI-1 as an inhibitor of metastasis in human prostate cancer	Russell PJ, Glover H
1996-1997	Workcover NSW ~$150,000	Validation of a monoclonal antibody test for the early detection of bladder cancer	Russell PJ1 Kingsley E, Yu Y
1996-1998	NSW Cancer Council $156,000	Methylation of tumour suppressor and tumor related genes in prostate cancer.	Clark S, Molloy PL, Russell PJ
1995-1997	NHMRC Category 1 $294,000	A predictive assay for radiotherapy response in bladder cancer	Russell PJ, Braithwaite AW
1995-1997	NHMRC Category 1 $311,322	Prostate cell specific expression of a toxin gene delivered by recombinant adenovirus vectors	Russell PJ, Molloy PL, Both GW.
1995-1997	NSW Cancer Council Category 1 $175,500	Cellular mechanisms involved in the development of androgen-independence and metastases of prostate cancer	Russell PJ, Brown J
1994-1995	AINSE $6,000	Low dose irradiation of human bladder tumours	Russell PJ
1994	Leo and Jenny Cancer and Leuaemia Foundation of Australia $40,784	Improved targeting of platinum anticancer drugs in breast and genitourinary tumours	Russell PJ, Hambley T, McKeage M.
1993	Clive and Vera Ramaciotti Foundation $15,000	Monoclonal antibodies for the treatment of bladder cancer	Russell PJ
1992	Prince Henry Hospital Centenary Research Fund $25,000	Autocrine growth factor interactions in human bladder cancer	Russell PJ, Brown JL, Nash AR.
1992	Department of Health $35,000	Care and maintenance of a nude mouse facility	Russell PJ, Vincent PC.
1991-1994	AMRAD $900,000	Therapeutic studies of human bladder cancer using monoclonal antibodies	Russell PJ, Garsia R, Person B, Pearce N, Raghavan D.
1991	University of Sydney Cancer Research Fund $28,000	Nude mouse consortium: Maintenance of nude mice for use in cancer research	Russell PJ
1991 -1992	AMRAD $83,000	Use of monoclonal antibodies for the diagnosis of human bladder cancer	Russell PJ, Walker KZ, Garsia R, Raghavan D
1991-1992	Worksafe Australia $90,000	Screening of voided urine for occupational bladder cancer	Garsia R, Russell PJ, Kenyon R, Pearson B.
1991	Royal Prnce Alfred Hospital Medical Fund $22,000	Cellular and Molecular studies of human bladder and prostate cancer.	Russell PJ, Raghavan D.
1991	Leo and Jenny Leukaemia & Cancer Foundation of Australia $46,535	Analysis of expression and mutations of p53 and fms genes in urine cells of cancer patients.	Russell PJ, Grimmond S.
1991-1993	NHMRC Category 1 $139,783	Significance of abnormal expression or mutation of genes in bladder cancer	Russell PJ, Rozinova E, Grimmond S.
1990-1991	NHMRC Category 1 $82,196	Experimental studies of heterogeneity of response to chemotherapy in bladder cancer	Raghavan D, Bell D, Russell PJ, Foo T.
1990	Australian Kidney Foundation (equipment) $5,000	Development of nude rat xenograft models for studies of intravesical therapy of human bladder cancer using radiolabelled monoclonal antibodies.	Russell PJ
1990	Leo and Jenny Leukaemia & Cancer Foundation of Australia $15,000 (equipment)	Predicting response of bladder cancer to anti-cancer drugs	Russell PJ, Raghavan D.
1990	University of Sydney Cancer Research Fund $30,000	Diagnosis and therapy of human bladder cancer monoclonal antibodies	Walker KZ, Russell PJ
1990	University of Sydney Cancer Research Fund $26,000	Maintenance of nude mice for use in cancer research	Russell PJ, Raghavan D, Basten A, Mountford C.
1989	University of Sydney Cancer Research Fund $15,000	Maintenance of nude mice for cancer research	Nude mouse consortium (convenor PJ Russell).
1988	University of Sydney Cancer Research Fund $23,000	Diagnosis and management of human bladder carcinomas using murine monoclonal antibodies	Walker KZ, Russell PJ
1988	Leo and Jenny Leukaemia & Cancer Foundation of Australia $22,000	Salary for animal house attendant	Nude mouse consortium (convenor PJ Russell).
1988	Leo and Jenny Leukaemia & Cancer Foundation of Australia $29,546 (equipment)	Development of metastasis and invasion of human solid tumours	Russell PJ, Grant A
1988-1990	NHMRC Category 1 $212,796	Studies of gene expression, rearrangement and mutation in urogenital cancers.	Russell PJ, Raghavan D
1986	NSW State Cancer Council Category 1 $12,424	Protein chemistry of phenotypic variants of prostate cancer	Raghavan D, Russell PJ
1986	NSW State Cancer Council Category 1 $25,000	Small cell undifferentiated carcinoma of the prostate: a model of tumour heterogeneity and studies of polypeptide hormone production.	Raghavan D, Russell P, Russell PJ
1986-1987	NHMRC Category 1 $114,469	Heterogeneity and differentiation of cancers of the genitourinary tract	Raghavan D, Russell PJ, Vincent PC.

Prof Russell has procured more than $36 million in grants, has published more than 200 papers in international journals (H factor 53), and has co-authored six patents.

Research interests

prostate cancer, nanoparticles for imaging and delivery of chemotherapy, gene therapy for late stage prostate cancer, exosomes (small vesicles secreted by cancer cells), origin of cancer cells, identifying biomarkers from protein, miRNA, RNA, DNA or lipid content, animal models of prostate cancer, targeted gene therapy,chemotherapy, castrate resistant prostate cancer, and bony metastasis

Top publications

Of 220 papers, 1 book , editor of 1 book, 19 book chapters...

Russell PJ, Hicks JD, Burnet FM. Cyclophosphamide treatment of kidney disease in (NZB x NZW)F1 mice. Lancet, 1966; June 11, 287(7450):1279‑84 (Leading article). PMID: 4160875 (121 citations, Google Scholar). This paper describes the first use of cyclophosphamide for potentially treating systemic lupus erythematosus (SlE) in an animal model of disease. Cyclophosphamide is still used clinically to treat cases of SLE that are refractory to steroid therapy.

Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, Jelbart M, Wass J, Zbroja R, Vincent PC. Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res, 1986; 46(4 Pt2):2035‑40. PMID: 2418959. This paper describes the establishment of a series of patient derived xenografts of human bladder cancer, shows that these are extremely heterogeneous with respect to flow cytometry, and histology, and indicates for the first time effective treatment using carboplatin, which has subsequently been adopted into the clinic.

Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer: advances and innovations. N Eng J Med, 1990; 322(16):1129-38 Reply: N Eng J Med, 1991; 324:126. PMID: 2181313. This classic paper provided expert information about management and biology of bladder cancer.

Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ. Cytosine Deaminase-Uracil Phosphoribosyl Transferase and Interleukin-12 and -18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 2009;15(7):2323-2234. PMID19318483. This paper shows that gene therapy and immunotherapy are synergistic against prostate cancer.

Pearce A, Simpson JD, Fletcher NL, Houston ZH, Fuchs, Whittaker AK, Russell PJ, Thurecht KJ. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic. Biomaterials, 2017;141:330-339. PMID:8711780 https://doi.org/10.1016/j.biomaterials.2017.07.004. This work uses a theranostic targeted to prostate cancer using a small molecule that binds to prostate specific membrane antigen. Both imaging and tumour regression were obtained.

More publications are available on PubMed

Team

Brian Tse Postdoctoral Research Fellow, APCRC-Q

Collaborators

Dr Warick D Heston, Lerner Institute, Cleveland Clinic, USA
Prof Andrew Whittaker and Dr Kristofer Thurecht, Australian Institute of Biotechnology and Nanotechnology, University of Queensland
Dr Benjamin Thierry, Ian Wark Institute, University of South Australia
Dr Jonathan Harris, Institute of Health and Biomedical Innovation, QUT
Dr David MacFarlane, FRACP, Director, Queensland Positron Emission Tomography Service, Deputy Director, Nuclear Medicine, Royal Brisbane & Women's Hospital, Queensland
Prof Andrew Boyd and Dr Jennifer Ellacott, Queensland Institute of Medical Research
Dr Michelle Hill, Diamantina Institute, University of Queensland

Professional memberships and associations

Membership of Professional Societies

Current	Urological Society of Australasia: Associate Member
Current	Gene Therapy group now Honorary Life member, Australian Society for Gene Therapy
Current	Associate member of American Association for Cancer Research
1991-2010	Member of Clinical Oncology Society of Australia
1993-2000	Founding Member, Genitourinary Cancer Urological Group
1998-1999	Vice-Chairman, Genitourinary Cancer Urological Group
1966-1995	Member of Australian Society for Immunology
1998	Executive Member, Australian Society for Gene Therapy
2007-2010	Secretary and Director, ANZUP Australian and New Zealand Prostate and Urological Cancer Clinical Trials Group Ltd
1995-2003	Founding member, and Director, Prostate Cancer Foundation of Australia
1995-2000	Peer review Committee, Prostate Cancer Foundation of Australia
2007 on	Member, Scientific Advisory Committee, ANZUP
2007 on	Member, Scientific Advisory Committee, ANZUP Prostate Cancer

Leadership in Professional Societies and Associations

1977-1978	Qualifications Committee of the Austrlaian Society of Microbiology
1979	Education Officer of the Australian society of Microbiology for ACT
1991	Member of Research Committee of COSA
1993	Founding member of Genitourinary Oncology Group GUOG
1995-1996	Secretary, GUOG
1998-1999	Vice-Chairman, GUOG
1998	Executive, Gene Therapy Group, NSW
1998-2000	Board Member, Prostate Cancer Research Foundation
2002-	Member of Bioresource Committee, APCC
2004-	Executive Member, APCC
2002-2004	Member of Board of Management of Biological Resources Centre (BRC), UNSW
2004-2006	Member of Advisory Committee of Biological Resources (BRAAG), UNSW
2004-	Member of IP Committee, St Vincents Hospital, Sydney
2003-2006	Member of Cancer Care Committee, South Eastern Sydney Area Health Service
2005-2006	Executive member, Scientific steering Committee, Prostate Cancer Foundation of Australia
2006-	Executive Member, Urological Oncology Program, NSW Cancer Institute
2007-2010	Secretary, Director, Australian Prostate and Urological Cancer Clinical Trials Group, ANZUP,

Sections